Tests CBL0137 with ipilimumab and nivolumab in advanced melanoma
Tests a new drug, CBL0137, with two immunotherapy drugs in adults with melanoma.
Key facts
- Who runs it
- Fox Chase Cancer Center
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 12 people, planned
- Started
- 30 Nov 2022
- Expected to end
- 2 Sept 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- CBL0137
- Ipilimumab
- Nivolumab
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that has spread to nearby lymph nodes or elsewhere in the body and can be biopsied repeatedly. It tests CBL0137 together with ipilimumab and nivolumab.
- Age
- Over 18 years
- Sex
- All sexes
- Disease stage
- Stage III melanoma with one or more lymph node metastases that can be biopsied or operated on, or stage III or stage IV disease that can be biopsied repeatedly, as judged by the treating doctor.
- Earlier treatment
- People who had earlier treatment targeting the CTLA-4 or PD1/PD-L1 pathway cannot join.
Main reasons for not taking part
- Taking any other investigational agent
- Known active autoimmune disease
- Earlier treatment targeting the CTLA-4 or PD1/PD-L1 pathway
- Another condition needing immunosuppressive medicine or high-dose steroids
- Ongoing diarrhea (more than 4 bowel movements a day) despite care in the 2 weeks before treatment
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients must have:; Pathologically proven stage III melanoma with one or more macroscopic lymph node metastases (measurable according to RECIST v. 1.1) amenable to biopsy and/or surgery OR:; Patients considered to have stage III or stage IV disease amenable to serial biopsies as determined by the treating physician. Note: patients with in-transit metastasis may be eligible after surgical consultation if not surgical candidates; Patients must have disease amenable to and must be willing to undergo protocol-directed repeat biopsies and blood draws
- Age > 18 years
- ECOG performance status 0 or 1
- Patients must have normal organ and marrow function
Who cannot take part
- Patients may not be receiving any other investigational agents
- Prior treatment with CTLA-4 or PD1/PD-L1 pathway targeted systemic treatment
- Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids
- Patients with ongoing diarrhea (> 4 bowel movements/day) unresolved despite medical and best supportive care in the two weeks preceding therapy
- Patients with a known active autoimmune disease
Where in United States
- Fox Chase Cancer CenterPhiladelphia, United StatesContact: Anthony J. OlszanskiTaking people
About the trial
What the trial wants to find out
Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.
The 3 groups in the trial
- CBL0137 (Dose level 1) +Ipilimumab + NivolumabTreatment being tested
Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
Treatment: CBL0137, Ipilimumab, and Nivolumab
- CBL0137 ( Dose level 2) +Ipilimumab + NivolumabTreatment being tested
Dose level 2 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
Treatment: CBL0137, Ipilimumab, and Nivolumab
- CBL0137 ( Dose level -1) +Ipilimumab + NivolumabTreatment being tested
Dose level -1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
Treatment: CBL0137, Ipilimumab, and Nivolumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- MEL-212: A Phase I Proof-of-Concept Study of CBL0137 (Curaxin) Combined With Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
- Plain-language title
- Tests CBL0137 with ipilimumab and nivolumab in advanced melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 May 2026